Redeye returns with updated estimates and valuation following Sleep Cycle's Q2 2026 report, presentation and webcast Q&A. We lower sales estimates by 3–5% for 2026e–2028e and lift 2026e EBIT to align with guidance. We trim our fundamental DCF-based valuation (Base Case) to SEK33, while Sleep Cycle now scores as 'Fairly Priced' on Redeye's new proprietary Value Score, implying a Fair Value of SEK31.
LÄS MER
